News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Anatara Lifesciences AGM Presentation



11/15/2016 11:38:36 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
Brisbane, Nov 15, 2016 - (ABN Newswire) - Anatara Lifesciences Ltd (ASX:ANR) is pleased to provide the company's AGM Presentation held on 15 November 2016.

Oral therapeutics for gastrointestinal disease in livestock and humans

Detach(TM)

- Natural, safe, non-antibiotic therapeutic that prevents and treats gastrointestinal diseases, including diarrhoea

- Meets the need to reduce the use of antibiotics in animal production

- Unlike antibiotics, Detach(TM) will not contribute to antimicrobial resistance

Market Opportunity is clear

- Detach(TM) addresses a major need - the livestock industry need effective alternatives to antibiotics to prevent diarrhoea

- Global animal antibiotic market valued at ~ $4.6 billion in 2014. Production animals 70%. Pigs lead by market share of 25%.

- Pork is #1 consumed meat in the world

- Global demand for meat is rising. More than 85% more meat needed by 2030.

- Governments are banning antibiotics for growth promotion and restricting prophylactic use in animal production

- Consumers want their meat to be safe

- Retailers are pledging to offer 'antibiotic free' meat

FY16 - Key Achievements

Milestone

Partnering

Zoetis have exclusive worldwide right (excl. AU/NZ) to evaluate Detach(TM) for veterinary use in livestock

Animal safety trials

Detach(TM) proven safe in piglets even when administered at 5x and more frequent than the recommended dose

Submission of dossier to APVMA

Anatara's application for registration of Detach was lodged with the APVMA (post reporting period).

Detach(TM) Poised for swift market entry - Commercially validated, supported by demand

- A clear path to market: Launch in 2017

-- Proven efficacy on commercial pig farms (therapeutic claims)

-- Proven safety (active ingredient is GRAS)

-- Manufacturing complete at commercial scale and global supply confirmed

- Introduction of DetachTM is supported by industry, government, retailer & consumer demand

- Commercially validated

- Detach(TM) will be supplied in Australia via preexisting distribution channels (Australian pork industry is heavily consolidated)

Detach(TM) for Humans Status

- Mode of action clearly understood, based on decades of research

- Pre-clinical efficacy database is very strong due to leverage of Detach(TM) data from pig studies

- Proof of concept in several animal models

- Confirmed efficacy in rabbit models with human diarrhoea pathogens

- Proof of concept in mouse model of inflammatory bowel disease

- Margin of safety studies (1x, 3x and 5x dose) in piglets completed (TAS study)

- Human Safety studies (Phase I) in healthy volunteers completed

-- 28 day treatment was very well tolerated

To view the presentation, please visit: http://abnnewswire.net/lnk/9152W055

About: Anatara Lifesciences Ltd

Anatara Lifesciences (ASX:ANR) is developing therapeutics for gastrointestinal diseases in production animals and humans. Its lead product Detach(TM) is a natural plant based product that will help address global concerns around the overuse of antibiotics in production animals that is contributing to the rise of so-called "super bugs" that make infectious diseases harder to treat. The Anatara team has a strong track record in biological science as well as building and growing international biotech companies.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES